Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$23.26M, compared with $20.75M a year earlier. Trailing-twelve-month net change in cash was -$69.75M. Over 3 fiscal years it compounded at +12.7% a year.
Context
- Net change in cash increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$23.26M or moves back toward the trailing-twelve-month quarterly average of -$17.44M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (25.74M) USD
- Year-over-year change
- -423.6%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.74M) | -423.6% |
| FY2024 | 2024-12-31 | 7.95M | -74.4% |
| FY2023 | 2023-12-31 | 31.03M | +272.6% |
| FY2022 | 2022-12-31 | (17.98M) | -2396.4% |
| FY2021 | 2021-12-31 | 783K | — |
Net Change in Cash vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 net change in cash of $69.75M is the 3rd largest of the 10 companies compared; the peer median is $3.89M.
- Its year-over-year change of +211.9% is the 3rd highest of 10, against a peer median of -46.3%.
- Over three fiscal years its annual growth of +12.7% compares with a peer median of -38.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $79.05M | -221.2% | +105.0% | 50.3% | |
| LTM Mar 2026 | $72.93M | +856.8% | -54.9% | 1024.0% | |
| LTM Mar 2026 | $69.75M | +211.9% | +12.7% | — | |
| LTM Mar 2026 | $32.55M | -179.4% | — | 32.7% | |
| LTM Mar 2026 | $21.06M | +126.4% | — | — | |
| LTM Mar 2026 | $15.19M | +3411.8% | +74.6% | 191.4% | |
| LTM Mar 2026 | $10M | -331.8% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $9.45M | -46.3% | -38.9% | — |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $8.83M | +125.8% | — | 123.6% |
| LTM Mar 2026 | $3.89M | -67.3% | -39.8% | 2905.2% | |
| Peer median (excluding PLRX) | $3.89M | -46.3% | -38.9% | 157.5% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Depreciation & Amortization | 1.54M | 1.82M | 1.84M | 2.13M | 1.7M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.44M | 22.6M | 44.48M | 37.63M | 26.23M |
| Change in Working Capital | 6.92M | 4.22M | 1.25M | 9.09M | (15.94M) |
| Accounts Receivables | 7.28M | 15K | 1.98M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 891K | (1.35M) | 2.97M | 1.43M | (5.48M) |
| Other Working Capital | (1.26M) | 5.55M | (3.7M) | 7.66M | (10.46M) |
| Other Non-Cash Items | 2.93M | 52K | (2.6M) | 5.96M | 9.02M |
| Operating Cash Flow | (75.44M) | (94.63M) | (116.36M) | (155.5M) | (128.34M) |
| Capital Expenditures | (1.95M) | (1.76M) | (921K) | (3.85M) | (374K) |
| Acquisitions (Net) | (75.65M) | 148.44M | 0 | 0 | 155K |
| Purchases of Investments | (219.89M) | (325.72M) | (583.07M) | (211.29M) | (203.4M) |
| Sales of Investments | 295.54M | 177.27M | 456.98M | 355.47M | 337.91M |
| Other Investing Activities | 75.65M | (148.44M) | 0 | 0 | 0 |
| Investing Cash Flow | 73.7M | (150.2M) | (127.01M) | 140.34M | 134.29M |
| Debt Repayment | 0 | 10M | 0 | 19.91M | (32.27M) |
| Common Stock Issued | 2.98M | 215.64M | 275.25M | 3.21M | 570K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (457K) | 1.21M | 5M | 0 | 0 |
| Financing Cash Flow | 2.53M | 226.85M | 274.41M | 23.12M | (31.7M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 783K | (17.98M) | 31.03M | 7.95M | (25.74M) |
| Free Cash Flow | (77.4M) | (96.39M) | (117.28M) | (159.35M) | (128.71M) |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.